New drug combo aims to outsmart aggressive leukemia

NCT ID NCT02428543

Completed Disease control Sponsor: Versailles Hospital Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests whether adding the targeted drug ponatinib to standard chemotherapy (cytarabine) can help prevent relapse in adults with a specific, high-risk genetic form of acute myeloid leukemia (FLT3-ITD AML) who are already in first remission. The study includes two age groups (18–60 and up to 70 years) and will first find the safest dose of ponatinib, then evaluate how well the combination works. The goal is to improve long-term survival for patients whose leukemia has a poor outlook with standard treatment alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ponatinib and cytarabine
What this could lead to: If successful, this combination could improve remission duration and survival for people with a high-risk genetic form of AML.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. Ponatinib can cause serious side effects like blood clots and liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia, FLT3 internal tandem duplication

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LUKEMIA

Contacts and locations

Show contact details

Locations

CHRU Dupuytren

Limoges, 87042, France
CHU Boulogne Sur Mer

Boulogne-sur-Mer, 62321, France
CHU Nice, Hôpital Archet 1

Nice, 06202, France
CHU d'Angers

Angers, 49033, France
CHU de Besançon

Besançon, 25030, France
CHU de Dijon

Dijon, 21079, France
CHU de Nîmes

Nîmes, 30029, France
Centre Hospitalier René Dubos

Pontoise, 95303, France
Centre Hospitalier René Huguenin

Saint-Cloud, 92210, France
Centre Hospitalier de Meaux

Meaux, 77104, France
Centre Hospitalier de Valenciennes

Valenciennes, 59322, France
Centre hospitalier de Versailles

Le Chesnay, 78157, France
Chr Clemenceau

Caen, 14033, France
Chu Amiens

Amiens, 80054, France
Dr Abdelaziz CHAIB

Aix-en-Provence, 13600, France
Dr Arnaud PIGNEUX

Pessac, 33604, France
Dr Christian RECHER

Toulouse, 31000, France
Dr Edouard RANDIAMALALA

Bayonne, 64100, France
Dr Emilie LEMASLE

Rouen, 76000, France
Dr Jacques DELAUNAY

Nantes, 44000, France
Dr Laurence SANHES

Perpignan, 66000, France
Dr Mario OJEDA-URIBE

Mulhouse, 68000, France
Dr Regis COSTELLO

Marseille, 13000, France
Dr Réda GARIDI

Saint-Quentin, 02100, France
Dr Stéphanie HAÏAT

Corbeil-Essonnes, 91100, France
Dr Thorsten BRAUN

Bobigny, 93000, France
Hôpital Claude Huriez

Lille, 59037, France
Hôpital Edouard Herriot

Lyon, 69437, France
Hôpital Henri Mondor

Créteil, 94010, France
Hôpital La Pitié Salpêtrière

Paris, 75013, France
Hôpital Necker Enfants Malades

Paris, 75743, France
Hôpital Saint Antoine

Paris, 75751, France
Hôpital Saint Louis

Paris, 75010, France
Hôpital VICTOR DUPOUY

Argenteuil, 95107, France
Hôpital d'Instruction des Armées PERCY

Clamart, 92141, France
Institut de Cancérologie de la Loire

Saint-Priest-en-Jarez, 42270, France
Marc BERNARD

Rennes, 35000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.